NCT06001788 2025-12-03
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Clinical Trials
7 trialsNCT02652871 2019-11-15
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02905994 2018-05-04
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
Phase 1 Withdrawn
NCT00093483 2014-01-13
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT00003268 2013-08-02
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00505700 2010-09-24
VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia
Massachusetts General Hospital
Phase 1 Completed
NCT00107523 2010-09-21
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 1 Completed